News | Pharmaceuticals | November 24, 2015

Federal Circuit Overturns District Court Decision on Bivalirudin Patents

Court grants The Medicines Company’s request for rehearing of appeal

November 24, 2015 —The U.S. Court of Appeals has overturned a federal circuit court’s decision in The Medicines Company v. Hospira Inc., supporting the patents claims for bivalirudin (Angiomax). This vacates the court’s earlier decision invalidating the Orange Book patents covering bivalirudin that expire in 2028 (pediatric exclusivity expiring in 2029). 

The court requested briefing concerning the commercial on-sale bar issue. It has requested the views of the United States Department of Justice, and will also allow other amicus curiae to submit their views. An amicus curiae is someone who is not a party to a case and offers information that bears on the case, but who has not been solicited by any of the parties to assist a court.

“We are extremely pleased that the invalidity decision has been vacated, and that the entire Appeals Court will now review the issue anew,” said Clive Meanwell, M.D., Ph.D., chief executive officer, The Medicines Company. “We continue to believe that our patents are valid and infringed by the ANDA filers, and are now considering all of our options with respect to Hospira, Mylan and other generics.”

For more information: themedco.com

Related Content

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init